Limits...
Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.

Mei Q, Li F, Quan H, Liu Y, Xu H - Cancer Sci. (2014)

Bottom Line: Busulfan has been widely used to treat CML.Moreover, a series of loss-of-function and gain-of-function experiments further indicated that busulfan may have its anti-osteosarcoma effect by upregulating the microRNA-200 (miR-200) family which subsequently downregulated its target genes ZEB1 and ZEB2.Taken together, our data suggest that busulfan may have an anti-osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR-200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.

View Article: PubMed Central - PubMed

Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.

Show MeSH

Related in: MedlinePlus

Measurements of cell viability, proliferation, apoptosis, senescence, and reactive oxygen species (ROS) levels in busulfan-treated osteosarcoma cells. (a) Percentage of viable cells (U2OS and MG-63) 24 h after different doses of busulfan. (b) Busulfan (100 μM) significantly inhibited the proliferation of U2OS and MG-63 cells. (c) Busulfan increased the apoptosis of U2OS and MG-63 cells. (d) Quantification of β-Gal positive cells in busulfan-treated U2OS and MG-63 cells. (e,f) 2'-7'-Dichlorodihydrofluorescein diacetate (DCF-DA) levels in U2OS after the different doses of busulfan treatment by representative cytometry histogram (e) and by quantification (f). MFI, mean fluorescence intensity. *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317920&req=5

fig01: Measurements of cell viability, proliferation, apoptosis, senescence, and reactive oxygen species (ROS) levels in busulfan-treated osteosarcoma cells. (a) Percentage of viable cells (U2OS and MG-63) 24 h after different doses of busulfan. (b) Busulfan (100 μM) significantly inhibited the proliferation of U2OS and MG-63 cells. (c) Busulfan increased the apoptosis of U2OS and MG-63 cells. (d) Quantification of β-Gal positive cells in busulfan-treated U2OS and MG-63 cells. (e,f) 2'-7'-Dichlorodihydrofluorescein diacetate (DCF-DA) levels in U2OS after the different doses of busulfan treatment by representative cytometry histogram (e) and by quantification (f). MFI, mean fluorescence intensity. *P < 0.05.

Mentions: Two osteosarcoma cell lines (U2OS and MG-63) were treated with busulfan for 48 h in culture, and the viable cells were detected by Trypan blue exclusion test. We found that busulfan reduced the cancer cell viability in a dose-dependent manner (Fig. 1a). As a concentration of 150 μM potentially decreased cell viability by more than 70% in both lines, it was thus applied in the following experiments.


Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.

Mei Q, Li F, Quan H, Liu Y, Xu H - Cancer Sci. (2014)

Measurements of cell viability, proliferation, apoptosis, senescence, and reactive oxygen species (ROS) levels in busulfan-treated osteosarcoma cells. (a) Percentage of viable cells (U2OS and MG-63) 24 h after different doses of busulfan. (b) Busulfan (100 μM) significantly inhibited the proliferation of U2OS and MG-63 cells. (c) Busulfan increased the apoptosis of U2OS and MG-63 cells. (d) Quantification of β-Gal positive cells in busulfan-treated U2OS and MG-63 cells. (e,f) 2'-7'-Dichlorodihydrofluorescein diacetate (DCF-DA) levels in U2OS after the different doses of busulfan treatment by representative cytometry histogram (e) and by quantification (f). MFI, mean fluorescence intensity. *P < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317920&req=5

fig01: Measurements of cell viability, proliferation, apoptosis, senescence, and reactive oxygen species (ROS) levels in busulfan-treated osteosarcoma cells. (a) Percentage of viable cells (U2OS and MG-63) 24 h after different doses of busulfan. (b) Busulfan (100 μM) significantly inhibited the proliferation of U2OS and MG-63 cells. (c) Busulfan increased the apoptosis of U2OS and MG-63 cells. (d) Quantification of β-Gal positive cells in busulfan-treated U2OS and MG-63 cells. (e,f) 2'-7'-Dichlorodihydrofluorescein diacetate (DCF-DA) levels in U2OS after the different doses of busulfan treatment by representative cytometry histogram (e) and by quantification (f). MFI, mean fluorescence intensity. *P < 0.05.
Mentions: Two osteosarcoma cell lines (U2OS and MG-63) were treated with busulfan for 48 h in culture, and the viable cells were detected by Trypan blue exclusion test. We found that busulfan reduced the cancer cell viability in a dose-dependent manner (Fig. 1a). As a concentration of 150 μM potentially decreased cell viability by more than 70% in both lines, it was thus applied in the following experiments.

Bottom Line: Busulfan has been widely used to treat CML.Moreover, a series of loss-of-function and gain-of-function experiments further indicated that busulfan may have its anti-osteosarcoma effect by upregulating the microRNA-200 (miR-200) family which subsequently downregulated its target genes ZEB1 and ZEB2.Taken together, our data suggest that busulfan may have an anti-osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR-200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.

View Article: PubMed Central - PubMed

Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.

Show MeSH
Related in: MedlinePlus